Integrated analysis of safety data from 12 clinical interventional studies of plasma‐ and albumin‐free recombinant factor VIII (r AHF ‐ PFM ) in haemophilia A-Reference-Cited by-同舟云学术

Integrated analysis of safety data from 12 clinical interventional studies of plasma‐ and albumin‐free recombinant factor VIII (r AHF ‐ PFM ) in haemophilia A

Published:2015-05-25 Issue:6 Volume:21 Page:791-798
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Shapiro A. D.¹,Schoenig‐Diesing C.²,Silvati‐Fidell L.³,Wong W. Y.⁴,Romanov V.²

Affiliation:

1. Indiana Hemophilia and Thrombosis Center Indianapolis INUSA

2. Global Medical Affairs Baxter HealthcareWestlake Village CA USA

3. Biostatistics Department Baxter Healthcare CorporationWestlake Village CA USA

4. Research and Development Baxter Healthcare Westlake Village CA USA

Funder

Baxter Healthcare Corporation

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12724

Reference27 articles.

1. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

2. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray GL;Blood,1994

3. Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A

4. A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A

5. Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2022-01-13

2. Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study;Journal of Clinical Medicine;2021-12-18

3. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2021-11-11

4. Efficacy safety and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2021-10-15

5. Recurrent events modelling of haemophilia bleeding events;Journal of the Royal Statistical Society: Series C (Applied Statistics);2021-01-07